ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Free Report) shares were down 1.7% during mid-day trading on Monday . The stock traded as low as $24.00 and last traded at $24.00. 14,576 shares were traded during trading, an increase of 58% from the average session volume of 9,221 shares. The stock had previously closed at […]
Stratos Wealth Partners LTD. boosted its stake in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO – Get Rating) by 5.0% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 6,444 shares of the company’s stock after buying an additional 309 shares during the period. Stratos Wealth Partners LTD.’s holdings in ALPS Medical Breakthroughs ETF were […]
Numab Therapeutics AG (Numab) and 3SBio Inc. ("3SBio", HKEX:1530) announced today that 3SBio's subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. ("Sunshine Guojian") exercised its option
2BScientific introduces LSBio as a new Supply Partner for UK and Ireland
UPPER HEYFORD, England, Feb. 1, 2021 /PRNewswire/ 2BScientific, leading UK based distributor of life science reagents, is delighted to announce that it has entered into partnership with LSBio, to distribute the US based company s portfolio of IHC validated reagents.
LSBio boasts an impressive catalogue of antibodies that have been tested in-house to ensure they are of the highest quality. Notably, their IHC-plus range of antibodies have been validated in-house to meet exacting standards of strong correlation to the published data and enhanced signal-to-noise ratio. The Path-Plus range represent the gold standard of antibodies and have been highly validated for use in specific areas of pathology.
Terms of the transaction were not disclosed.
LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The Company has built a catalog of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its acquisition of Absolute Antibody and Kerafast further expands its product portfolio by adding a range of unique reagents and antibody services.
Absolute Antibody specializes in recombinant antibody technology, offering antibody sequencing, engineering and recombinant production as custom services, as well as a unique catalog of recombinant antibodies and Fc Fusion proteins, engineered into new and useful formats. In 2018, Absolute Antibody merged with Kerafast Inc., a Boston-based company that facilitates access to unique laboratory-made reagents, to further the availability of recombinant antibodies. The new acquisition combines a strong recombinant antibody portfolio with LSBio’s